Are microRNAs in urine biomarkers of multiple myeloma?
Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple myeloma.
Despite the improvement of treatments over the last three decades, the mortality of patients with NFAs in our series remains high. Apart from age, factors related with the management/outcome of the tumor are not independent predictors, and pituitary hormone deficits managed with the currently-used substitution protocols do not adversely affect mortality.